Effects of a Rheumatoid Arthritis Self-management Program

Status Completed

Clinical Trial Summary

Clinical Trial Description

Rheumatoid arthritis (RA) is a persistent systemic disease. WHO (World Health Organization) commented that a crucial goal of heath care for RA is prevention of loss of daily function by patients' self-management (SM) skills; however, a comprehensive rheumatoid arthritis self-management program for RA patients' day-to-day self-managing is limited in Taiwan. The aims of the study are: (1) to implement the rheumatoid arthritis self-management program, and (2) to determine the effectiveness of the program with 6 months follow-up. The project will design to implement and evaluate the rheumatoid arthritis self-management program for RA patients using two groups experimental design. A medical center in northern Taiwan will be selected and patients who visited the RA departments will be eligible for the study if they are: (1) diagnosed with RA, (2) age of 20 years or over, (3) disease considered have been stable for at least 3 months, and (4) able to understand and comply with the study treatment. After completion of baseline data, patients will be randomly allocated to the intervention or control group using a computerized allocation procedure and follow the CONSORT flow diagram. Control patients received usual care, and the intervention group will receive the 6-week rheumatoid arthritis self-management program which based on self-efficacy theory. The independent variable of the program will be the four information include mastery experience, social modeling, social persuasion and physical and emotional states, and the strategies involve education, goal setting and attainment, self-monitoring, and phone calls. All participants will follow up for 6 months, and the data will be collected at the baseline, and 2, 3, and 6 months. The statistics with the GEE (generalized estimating equation) analysis will be used to evaluate the outcomes such as the disease activity (DAS-28), arthritis self-efficacy (ASE), physical functioning (MHAQ), quality of life (SF-36), and self-management behaviors. Through enhance the capacity of self-management program for the RA cases to reduce the health care utilization and patients' and caregivers' burden. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03470740
Study type	Interventional
Source	Chang Gung Memorial Hospital
Contact
Status	Completed
Phase	N/A
Start date	September 1, 2016
Completion date	July 31, 2018

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT01682512` - Efficacy, Pharmacokinetics, and Safety of BI 695500 in Patients With Rheumatoid Arthritis	Phase 3
Completed	`NCT00539760` - A Phase I Rheumatoid Arthritis Study in Healthy Volunteers	Phase 1
Active, not recruiting	`NCT03312465` - Anatomical Shoulder Domelock System Study
Completed	`NCT01208181` - A Two-Part, 12-Week Study of Etoricoxib as a Treatment for Rheumatoid Arthritis (RA) (MK-0663-107)	Phase 3
Completed	`NCT03254810` - Comparison of the Safety and PK of SYN060 to Humira® in Healthy Adult Subjects	Phase 1
Completed	`NCT01711814` - A Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rheumatoid Arthritis Study	Phase 2
Completed	`NCT03315494` - Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of SKI-O-703 in Healthy Volunteers	Phase 1
Withdrawn	`NCT03241446` - Pharmacokinetics and Dosimetry of Tc 99m Tilmanocept Following a Single Intravenous Dose Administration in Male and Female Subjects Diagnosed With Rheumatoid Arthritis (RA)	Phase 1
Completed	`NCT02748785` - MTX Discontinuation and Vaccine Response	Phase 4
Completed	`NCT02553018` - Comparison of Compliance and Evolution of Functional Capacity of Patients With Rheumatoid Arthritis Treated by Methotrexate Either by Auto-injector or by Conventional Sub-cutaneous Syringe	Phase 3
Active, not recruiting	`NCT02260778` - Treat-to-target in RA: Collaboration To Improve adOption and adhereNce	N/A
Completed	`NCT02569736` - Characterization of the Effect of Tocilizumab in Vivo and in Vitro on T Follicular Helper Cells in Rheumatoid Arthritis Patients and Consequence on B Cells Maturation
Completed	`NCT01750931` - This Study is Randomised, Single Oral Dose Bioequivalence Study of Meloxicam GSK 15 MG Tablets.	Phase 2
Withdrawn	`NCT01204138` - Concomitant Use of Apremilast for the Treatment of Active RA Despite TNF-Inhibition and Methotrexate- CATARA	Phase 2
Not yet recruiting	`NCT01154647` - Pain Inhibition in Patients With Rheumatoid Arthritis and Central Sensitivity Syndromes	N/A
Completed	`NCT00913458` - Study Evaluating Etanercept Plus Methotrexate in Early Rheumatoid Arthritis	Phase 4
Completed	`NCT00973479` - An Effectiveness and Safety Study of Intravenous Golimumab in Patients With Active Rheumatoid Arthritis Despite Treatment With Methotrexate Therapy	Phase 3
Completed	`NCT00975130` - Subcutaneous Golimumab (GLM) Plus DMARDs for Rheumatoid Arthritis, Followed by Intravenous/Subcutaneous GLM Strategy (P06129 AM2)	Phase 3
Completed	`NCT00660647` - Optimized Treatment Algorithm for Patients With Early Rheumatoid Arthritis (RA)	Phase 3
Completed	`NCT00550446` - A Phase 2 Study For Patients With A Physician's Diagnosis Of Rheumatoid Arthritis	Phase 2